Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b/2a, 3-Part, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 Monotherapy and in Combination With Venetoclax in Subjects With Relapsed or Refractory Haematologic Malignancies

NCT03218683 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03218683
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03218683 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b/2a, 3-Part, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 Monotherapy and in Combination With Venetoclax in Subjects With Relapsed or Refractory Haematologic Malignancies
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Terminated
Start date
August 2, 2017
Completion date
October 8, 2021
Enrollment
70 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory acute myeloid leukemia (aml)